基于18F-FDG PET-CT的功能参数在软组织肉瘤患者中的预后价值：一项荟萃分析。

Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: A meta-analysis.

作者信息

Chen Linyan, Wu Xin, Ma Xuelei, Guo Linghong, Zhu Chenjing, Li Qingfang

机构信息

State Key Laboratory of Biotherapy and Cancer Center Department of Head and Neck Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.

出版信息

Medicine (Baltimore). 2017 Feb;96(6):e5913. doi: 10.1097/MD.0000000000005913.

BACKGROUND

Considering the clinical importance of high 5-year mortality, we performed a meta-analysis of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) from F-FDG PET-CT for overall survival (OS) and progression-free survival (PFS) in patients with soft tissue sarcoma.

METHODS

The search and selection of eligible articles was conducted on PubMed and EMBASE. We applied hazard ratio (HR) and odd ratio (OR) to measure the correlation between SUVmax, MTV, and TLG with PFS and OS. The SUVmax was analyzed through subgroup in terms of histological grade and HR of posttreatment SUVmax was also assessed.

RESULTS

Eleven studies with 582 patients were included. The pooled HRs of pretreatment SUVmax were 2.40 (95% CI: 1.38-4.17) for OS and 2.20 (95% CI: 1.47-3.30) for PFS. The HRs in terms of OS were 3.20 (95% CI: 1.71-5.98) based on MTV and 5.20 (95% CI: 2.34-11.56) based on TLG. Meanwhile, the predict results of pretreatment SUVmax on OR remained significant and the HRs of posttreatment SUVmax were 2.25 (95% CI: 1.33-3.80) for OS and 2.87 (95% CI: 1.81-4.55) for PFS.

CONCLUSIONS

The pretreatment SUVmax, MTV, and TLG of F-FDG PET-CT showed significant prognostic value for OS and the PET-CT can be used in identifying high-risk patients about progression and survival. The analysis for posttreatment SUVmax suggested PET-CT as a promising equipment in monitoring therapy response.

背景

鉴于5年高死亡率的临床重要性，我们对F-FDG PET-CT的最大标准化摄取值（SUVmax）、代谢肿瘤体积（MTV）和总病变糖酵解（TLG）进行了荟萃分析，以探讨其对软组织肉瘤患者总生存期（OS）和无进展生存期（PFS）的影响。

方法

在PubMed和EMBASE上进行合格文章的检索和筛选。我们应用风险比（HR）和比值比（OR）来衡量SUVmax、MTV和TLG与PFS和OS之间的相关性。通过组织学分级对SUVmax进行亚组分析，并评估治疗后SUVmax的HR。

结果

纳入了11项研究，共582例患者。治疗前SUVmax的合并HR在OS方面为2.40（95%CI：1.38-4.17），在PFS方面为2.20（95%CI：1.47-3.30）。基于MTV的OS的HR为3.20（95%CI：1.71-5.98），基于TLG的为5.20（95%CI：2.34-11.56）。同时，治疗前SUVmax对OR的预测结果仍然显著，治疗后SUVmax的HR在OS方面为2.25（95%CI：1.33-3.80），在PFS方面为2.87（95%CI：1.81-4.55）。